Low-Dose Methotrexate Exposure Minimally Increases Risk of Melanoma
Source: Rheumatology Network, August 2022
“Comprehensively defining the risk of melanoma associated with low-dose methotrexate is important for clinicians across several medical disciplines."
A systematic review and meta-analysis indicated that low-dose methotrexate, a commonly used treatment for a variety of inflammatory disorders, exposure was associated with a small increased risk of developing melanoma. However, after sensitivity analysis, the absolute risk was considered negligible, according to a study published in JAMA Dermatology.
“Globally, the incidence of melanoma is increasing, and it is projected to become the second most common cancer in the US by 2040,” investigators explained. “Despite decades of clinical use, some studies suggest that low-dose methotrexate may be associated with an increased risk of skin cancer.